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he Pathogenesis of Myocardial Fibrosis
n the Setting of Diabetic Cardiomyopathy
uan Asbun, MD, PHD,* Francisco J. Villarreal, MD, PHD†
exico City, Mexico; and San Diego, California
Diabetes has emerged as a major threat to worldwide health. The increasing incidence of
diabetes in young individuals is particularly worrisome given that the disease is likely to evolve
over a period of years. In 1972, the existence of a diabetic cardiomyopathy was proposed based
on the experience with four adult diabetic patients who suffered from congestive heart failure
in the absence of discernible coronary artery disease, valvular or congenital heart disease,
hypertension, or alcoholism. The exact mechanisms underlying the disease are unknown;
however, an important component of the pathological alterations observed in these hearts
includes the accumulation of extracellular matrix (ECM) proteins, in particular collagens. The
excess deposition of ECM in the heart mirrors what occurs in other organs such as the kidney
and peritoneum of diabetics. Mechanisms responsible for these alterations may include the
excess production, reduced degradation, and/or chemical modification of ECM proteins.
These effects may be the result of direct or indirect actions of high glucose concentrations.
This article reviews our state of knowledge on the effects that diabetes-like conditions exert
on the cells responsible for ECM production as well as relevant experimental and clinical
data. (J Am Coll Cardiol 2006;47:693–700) © 2006 by the American College of





























iuring the past three decades epidemiological, clinical, and
aboratory studies have confirmed the existence of a cardio-
yopathy associated with diabetes mellitus (DM). The
iagnosis of a diabetic cardiomyopathy is made in patients in
hom no other known etiological factors, such as coronary
rtery disease, alcoholism, or hypertension, are present (1,2).
n these patients, a higher incidence of congestive heart
ailure is observed (3). Pathological alterations include those
elevant to muscle tissue and cells, such as the presence of
yocardial hypertrophy and impaired contraction, those
ssociated with extracellular matrix (ECM) proteins, such as
xcess deposition of collagens, abnormal glycosylation/
rosslinking, and alterations in diastolic compliance (4).
ther abnormalities include those associated with the vas-
ular compartment, such as the thickening of the endothe-
ium basal lamina (5). This review focuses on the current
nowledge of pathogenesis of myocardial fibrosis in diabet-
cs. It also includes observations relevant to the topic of
issue fibrosis in diabetics as derived from various cells and
rgans.
RGAN FIBROSIS AS A PATHOLOGICAL
BSERVATION OF LONGSTANDING DIABETES
y far, diabetes-associated nephropathy is the pathological
ntity that has been best characterized and studied for any
rgan (6). It is well established that the chronic exposure of
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ccepted September 26, 2005.he kidney to hyperglycemic conditions favors the develop-
ent of extensive structural damage. Indeed, diabetic nephrop-
thy (DN) is a major cause of end-stage renal disease (7).
omparable structural changes occur in the glomeruli of
ither type 1 or type 2 diabetic patients (8,9). Most of these
hanges are associated with the ECM (10). Diabetic ne-
hropathy is associated with hypertrophy of glomerular and
ubular elements as well as the thickening of their basal
embrane. In addition, there is an excessive accumulation
f ECM proteins in the mesangium (glomerulosclerosis),
hich narrows or occludes the glomerulus lumen. Another
allmark of DN is the presence of tubulointerstitial fibrosis.
he severity of changes in the mesangium and tubules
ltimately correlates with loss of kidney function and
educed survival rates (10). The thickening of the glomer-
lar basal membrane is associated with increases in collagen
ype IV, laminin, and proteoglycans (11,12). In the mesan-
ium, there are increases in collagen types IV, V, VI,
bronectin, and laminin, as well as proteoglycans (12–14).
n latter stages of glomerulosclerosis, increases in types I and
II collagens occur (13). Animal models of diabetes mirror
tructural changes observed in human kidneys (10). In-
reases in the deposition of ECM proteins can be the result of
nhanced production and/or decreased degradation. Experi-
ental data support causative roles for altered ECM turnover
s assessed through changes in messenger ribonucleic acid
nd/or protein levels for ECM proteins, serine proteases (e.g.,
lasmin), matrix metalloproteinases (MMPs), or tissue inhib-
tors of MMPs (10).
Organs such as the peritoneum also can develop fibrosis
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Diabetes and Cardiac Fibrosis February 21, 2006:693–700enal disease are submitted to peritoneal dialysis (15). Over
he course of time, a significant proportion of patients on
eritoneal dialysis develop increased permeability of small
olutes, which enhances the absorption of glucose and
eads to the failure of ultrafiltration by the dissipation of
he osmotic gradient (15,16). Animal models of end-
tage renal disease have shown that the stimulation of
rofibrotic growth factor release (such as transforming
rowth factor [TGF]-beta-1) in the peritoneum is asso-
iated with the development of submesothelial fibrosis
nd it has been proposed that these events may be
otentiated in diabetics (17).
The chemical modification of existing proteins also can
ontribute to the development of fibrosis. Part of the aging
rocess includes the loss of elasticity of the vascular system,
eading to systolic hypertension secondary to enhanced
rterial stiffness. Patients with diabetes manifest increased
rterial stiffness at a younger age than their nondiabetic
ounterparts (18). These observations have led to the
oncept that the mechanism(s) that underlies changes in
rterial stiffness associated with aging is accelerated in
iabetes. Underlying the loss of tissue elasticity is a well-
nderstood nonenzymatic reaction between glucose and
roteins known as the Maillard or browning reaction (19).
he glycosylation of long-lived proteins can undergo further
hemical changes, yielding very stable complex products and
rosslinks known as advanced glycosylation end-products
AGEs) (Fig. 1) (19). This advanced glycation of proteins is
ccelerated in the presence of diabetes (18). The formation
f AGEs on vessels facilitates the crosslinking of long-lived
ollagen molecules to each other, increases resistance to
igure 1. Production of collagen crosslinks. Glucose interacts with collage
chiff base can then rearrange over a period of days to generate an Amado
n the reverse direction and, thus, glycated collagen accumulates. Glycated c
Abbreviations and Acronyms
AGE  advanced glycosylation end products
Ang II  angiotensin II
DAG  diacylglycerol
DM  diabetes mellitus
DN  diabetic nephropathy
ECM  extracellular matrix
HG  high glucose
LV  left ventricle/ventricular
MMP  matrix metalloproteinases
PKC  protein kinase C
ROS  reactive oxygen species
TGF  transforming growth factornd crosslinks known as advanced glycosylation end-products (AGEs). Collag
esistant to proteolysis.roteolysis, and thus yields fibrosis (18). There is also loss of
ollagen elasticity and reductions in arterial compliance.
dvanced glycosylation end products also are now recog-
ized as playing important roles in cell signaling by inter-
cting with specific receptors (e.g., RAGE) that link to the
ctivation of adhesion molecules, proinflammatory cyto-
ines, and growth factors, thus contributing to pathological
ntities such as atherosclerosis (20).
IBROSIS IN THE HUMAN DIABETIC HEART
ubler et al. (21) first recognized the existence of a diabetic
ardiomyopathy in patients with congestive heart failure
ho had no evidence of coronary atherosclerosis. Epidemi-
logic evidence of an association of a specific cardiomyop-
thy with diabetes became evident with the Framingham
tudy (22). Data showed a 2.4-fold greater incidence of
eart failure in diabetic men and a 5.1-fold increase in
omen. Studies conducted in the early 1980s demonstrated
hanges in myocardial vasculature of diabetic subjects (5).
ther studies also demonstrated evidence of left ventricular
LV) hypertrophy and fibrosis with various degrees of small
essel disease (23). Detailed pathological examinations re-
eal myocardial hypertrophy, interstitial fibrosis, capillary
ndothelial changes, and capillary basal laminae thickening
23). Microscopic alterations in small intramural coronary
rteries include the narrowing of the lumen due to increased
roliferation of endothelial cells, increased thickness of the
rteriolar wall due to fibrosis and accumulation of mucopo-
ysaccharides, alterations of elastic fibers, myocytolysis, and
erivascular fibrosis (5,24). The increased accumulation of
ollagen types I and III primarily are found in the epicardial
nd perivascular regions, whereas type IV is found in the
ndocardial layer (25).
Echocardiography of diabetic patients indicates the de-
elopment of LV hypertrophy (26). Analysis of data also
ndicates alterations in echocardiographic signals (backscat-
er reductions) in diabetic patients, which may reflect tissue
brosis or other cardiomyopathic changes. Noninvasive
tudies have shown alterations in both systolic and diastolic
unction in diabetics and, to a greater extent, those with
icrovascular complications and/or hypertension (4). The
mpairment of LV diastolic function of patients with dia-
etes may be secondary to alterations in collagen structure,
pecifically increased collagen crosslinking or AGEs (18).
orm a Schiff base. This reaction occurs fast and is reversible. The collagen
oduct (i.e., glycated collagen). This step occurs faster in the forward than
n can undergo further chemical modification to yield complex compoundsn to f
ri pr
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February 21, 2006:693–700 Diabetes and Cardiac Fibrosislinical studies have yielded positive correlations between
GE serum levels and isovolumetric relaxation time and
V diameter during diastole (27).
NIMAL MODELS OF DIABETIC CARDIOMYOPATHY
nimal models for the study of diabetes include those that
imic type 1 or type 2. An extensive review on the subject
as published recently (28). Factor et al. (29) first evaluated
he effects of hypertension and diabetes on rat myocardium
n 1981 and showed hypertensive-diabetic rats develop
ardiac hypertrophy and fibrosis. Subsequent results from
ein and Sonnenblick (3) indicated that diabetes alone did
ot yield morphological alterations in myocardium, but
nimals did exhibit weakened contraction. In a subsequent
tudy by Factor et al. (30), increases in cellular lipids and
yofibrinolysis were noted with patients with diabetes. The
ssessment of vascular lesions of hypertensive-diabetic rats
ndicated pronounced arteriolar constriction, which may
ave caused ischemic injury to the myocardium leading to
eplacement fibrosis (31). However, experimental studies in
iabetic dogs and monkeys have demonstrated interstitial
brosis and less compliant LVs (22). In addition, myocar-
ial hydroxyproline content and associated crosslinks were
ignificantly greater in the endocardium of diabetic pigs
32). Other studies also have examined the effects of
iabetes on LV remodeling after infarction showing that
iabetes decreases animal survival and exaggerates LV
emodeling after infarction while increasing interstitial fi-
rosis and myocyte apoptosis (33,34).
HE EFFECTS OF PHARMACOTHERAPY
harmacologic interventions have been used experimentally
n an attempt to retard or reverse the development of
tructural changes in the diabetic myocardium. Treating
iabetic rats with the angiotensin-converting enzyme inhib-
tor captopril for four months prevented increases in dia-
tolic pressure, coronary perfusion pressure, vascular resis-
ance, and interstitial and perivascular fibrosis (35). The
ngiotensin-converting enzyme inhibitor enalapril can nor-
alize glycation levels in the myocardium and reduce LV
tiffness (36). The beneficial effects of enalapril may be
erived at least in part by its antioxidant properties (37).
reatment of diabetic rats with the antifibrotic compound
irfenidone or the aldosterone blocker spironolactone atten-
ated increases in LV diastolic stiffness and reversed fibrosis
ithout normalizing contractility (38). Evidence from clin-
cal trials indicates that pathological cardiac remodeling can
e prevented or reversed with drugs that block neurohor-
onal systems, including the renin angiotensin system and
he sympathetic nervous system (39,40). These clinical trial
esults indicate that patients with diabetes benefit as much
s patients without diabetes from neurohormonal-inhibition
herapies (39,40). However, caution should be exercised in
xtrapolating pharmacologic therapy benefits demonstrated pn the general population to patients with diabetes in the
bsence of extensive clinical data.
The observation that AGE products may be partly
esponsible for the structural alterations observed in various
rgans, in particular blood vessels, led to the development of
rosslink breaker compounds such as aminoguanidine (18).
he administration of these compounds to diabetic dogs or
onkeys decreases the enhanced LV stiffness that develops
ith diabetes and improves contractile function (41,42).
he use of these compounds in rats yields the restoration of
V collagen solubility, brain natriuretic peptide serum
evels, and normalized gene expression for collagen type III
nd the profibrotic effector connective TGF (43). In a Phase
a study completed in January of 2003, the Distensibility
mprovement and Remodeling in Diastolic Heart Failure
DIAMOND) trial results indicated that treatment with
he crosslink breaker alagebrium resulted in a reduction in
V mass within a 16-week treatment period, as well as an
mprovement in LV diastolic filling and quality of life. The
ompound is currently undergoing further evaluation and
esting for its potential to improve diastolic function and
educe hypertrophy.
N VITRO MODELS OF DIABETES
wo main methods have been developed to examine effects
hat diabetes-like conditions have on in vitro ECM turn-
ver. The first uses primary cell cultures isolated from
ormal tissues exposed to high glucose (HG) so as to
imulate the hyperglycemic milieu of diabetes. The second
ses cells derived from either animal models of diabetes or
iabetic humans that are cultured in HG. Differences in
xperimental design are important in that results derived
rom both types of cultures may not concur. To better
imulate diabetes, most investigators also rely on protocols
hat include the long-term cultures of cells, typically no 2
o 3 days and up to weeks. Commonly used concentrations
f D-glucose are 25 to 30 mmol/l (450 to 540 mg/dl) to
epresent HG and 5 mmol/l (100 mg/dl) for normal
lucose. It is important to note that many culture systems
outinely used to examine changes in “normal” cell function
nadvertently include media with HG concentrations akin
o those of diabetes-like conditions (315 to 450 mg/dl,
espectively). In vitro experiments also have included the use
f fluctuating levels of HG as a possible treatment scheme
o better simulate diabetes spikes (44).
The in vitro assessment of hyperglycemic effects has been
ursued most extensively in mesangial and glomerular
pithelial cells. Published observations indicate that, in
ultured mesangial cells, the presence of 30 mmol/l glucose
for four weeks) yields an increase in ECM proteins such as
bronectin, laminin, and type IV collagen production
45,46). High glucose also increased mesangial cell diacyl-
lycerol (DAG) levels and protein kinase C (PKC) (47). To
etermine the mechanisms involved in enhanced ECM
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Diabetes and Cardiac Fibrosis February 21, 2006:693–700sing mesangial cells cultured in normal and HG condi-
ions. Under HG conditions, they observed a 40% to 50%
ncrease in the synthesis of fibronectin, laminin, and type IV
ollagen with no apparent change in total protein synthesis
r ECM protein degradation after one week. Studies by
ugliese et al. (49) indicate that in long-term cultures of rat
lomerular mesangial cells, HG increases fibronectin, lami-
in, and collagen IV and VI by week 2, with no changes in
otal protein or cell proliferation. Interestingly, D-galactose
nd L-glucose treatment (which can induce nonenzymatic
rotein glycosylation) mimicked in part D-glucose–induced
CM overproduction, suggesting this process is partially
esponsible for the effects.
The inhibition of cell proliferation also has been reported to
ccur when mesangial cells were grown in the presence of
lycated serum (serum exposed to 28 mmol/l of glucose for
our days) whereas type IV collagen gene expression and
ecretion were stimulated (50). Cell proliferation also was
nhibited by the use of culture plates precoated with glycated
erum. The use of a monoclonal antibody immunoreactive
ith Amadori adducts in glycated albumin blocked these effects.
Fibroblasts from other organs can also increase ECM
eposition when exposed to HG. Human skin fibroblasts
ultured in HG increase collagen III synthesis both at
RNA and protein levels (51). Known complications of
atients with DM also include retinopathy and neuropathy,
n which excess ECM production can play a role in their
athogenesis. Long-term culture with HG of bovine retinal
icrovessel pericytes stimulated protein and collagen syn-
hesis (52). In primary cell culture of sciatic nerves (a
ixture of Schwann cells, perineurial cells, and fibroblasts)
G increased collagen I, collagen IV, and fibronectin
RNAs (53).
Few reports on the effects of HG on cardiac fibroblasts
CF) have been published. The culture of human cardiac
yofibroblast in HG increases cell proliferation (54). In
eonatal rat cardiac fibroblasts, HG and osmotic control
edia increase DNA and collagen synthesis as well as
bronectin and TGF-beta-1 gene expression (55). Recently,
e assessed the effects that HG has on adult rat cardiac
broblast protein and collagen synthesis, MMP activity, and
ngiotensin II (Ang II) AT1 receptor mRNA levels (56).
e also determined whether co-treatment with Ang II
ielded additive or synergistic effects with HG, as the
dditive effects of HG and angiotensin II on type IV
ollagen synthesis have been previously reported in mesan-
ial cells (57). Our results indicated that HG-treated cardiac
broblasts synthesized more protein and collagen, but the
ddition of Ang II did not further stimulate these effects.
Interestingly, pretreatment with losartan blocked HG-
nduced increases in protein and collagen synthesis. HG also
ecreased total MMP activity, and the effect was blocked by
osartan. Notably, AT1 mRNA levels were up-regulated
ith HG. These results suggest that HG may promote
brosis by increasing CF protein and collagen synthesis and
ecreasing MMP activity and that HG may cause these pffects via the up-regulation of AT1 receptors. As discussed
n more detail to follow, the ability of HG to stimulate the
roduction of reactive oxygen species (ROS) in cells is well
stablished. As a result, we also determined the effects of
OS scavenger treatment on CF functions. Interestingly,
lthough pretreatment with vitamin E blocked the effects of
G on total protein synthesis, it stimulated MMP activity
ithout altering ECM synthesis. Thus, it is possible to
peculate that vitamin E treatment may normalize HG-
nduced increases in ECM synthesis by enhancing its
egradation.
The production/deposition of ECM induced by HG also
ay be organ/cell type dependent. In human gingival
broblasts, glucose concentrations from 5 to 50 mmol/l
esulted in a dose-dependent reduction of collagen synthe-
is. Total protein synthesis and cell number were not altered
58). In mouse proximal tubule epithelial cells, HG in-
reases ECM and total protein synthesis (59). In human
lomerular epithelial cells, HG induced the differential
xpression of integrins, decreased binding of the cells to type
V collagen, decreased MMP-2 gene expression, and in-
uced up-regulation of tissue inhibitor of MMP-2 (60). In
uman skin fibroblasts isolated from diabetic ulcer sites cell
roliferation is significantly slower versus control, and this
ifference persists regardless of the glucose concentration
sed in the media (61).
ARACRINE AND MECHANICAL FACTORS
t has been demonstrated that the exposure of ECM-
roducing cells to HG yields the synthesis/secretion of
aracrine factors that may mediate their functional re-
ponses. For example, in cultured human mesangial cells
xposed to HG, the production of Ang II was greater
ompared with controls and was prevented by a PKC
nhibitor (62). High glucose-induced increases in TGF-
eta-1, fibronectin, and type IV collagen were partially
locked by candesartan (an AT1 antagonist). Thus, HG
ppears to stimulate Ang II production via the activation of
KC, and Ang II partially mediates ECM synthesis (62).
uman peritoneal mesothelial cells cultured in HG yield
ncrease in basic fibroblast growth factor. Peritoneal fibro-
last proliferation was noted to increase when cells were
xposed to mesothelial cell HG-conditioned media, and
nti- basic fibroblast growth factor neutralizing antibody
locked the effects (63). In human peritoneal fibroblasts,
G increased TGF-beta-1 and type I collagen mRNA
evels in a dose-dependent manner. The use of TGF-beta-1
ntibodies blocked these effects (64). In murine renal cortical
broblasts, HG increased TGF-beta-1, -2, and -3 gene
xpression. High glucose and TGF-beta-1 also increased
he incorporation of proline, mRNA, and protein levels for
ype I collagen. Pan-selective TGF-beta antibodies attenu-
ted these effects. Therefore, HG and TGF-beta appear to
licit comparable effects on renal fibroblasts (65). Human
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February 21, 2006:693–700 Diabetes and Cardiac Fibrosisxposed to HG show increases in cell proliferation and
ecretion of TGF-beta-1 and platelet-derived growth factor.
hen exposed to intermittent HG, there are further in-
reases in proliferation, TGF-beta-1 secretion, protein con-
ent, and collagen synthesis. Thus, pulsating glucose excursions
ay have important pathophysiologic effects on human tubulo
nterstitial structure (66).
Mechanical stimuli also may play roles in stimulating cell
unction. In isolated perfused glomeruli from diabetic rats,
lomerular compliance is known to increase with time.
hen stretched, mesangial cells increase total collagen
ynthesis in both normal glucose (NG) (50%) and HG
onditions (27%). However, the fraction of newly formed
ollagen being catabolized also increased in NG conditions,
ut was unchanged with HG, which results in an increase in
et collagen accumulation with HG (67).
EACTIVE OXYGEN SPECIES
esults from in vitro experiments indicate that the genera-
ion of ROS is likely involved in inducing abnormal re-
ponses to HG (68). High glucose induces ROS generation
n mesangial and tubular epithelial cells and up-regulates
GF-beta-1 and ECM synthesis (45,69,70). These effects
lso can be mimicked by H2O2 (71). The use of 3-O-
ethyl-D-glucose or L-glucose does not induce intracellular
OS, and cytochalasin B (a glucose transporter inhibitor)
nhibits D-glucose–induced intracellular ROS, suggesting
hat HG-induced ROS depends on glucose uptake and
etabolism (69). The source of HG-induced ROS gener-
tion appears to be linked to the NADPH oxidase system
nd mitochondrial metabolism (68). Further evidence of the
nvolvement of ROS comes from the observation that the
reatment of mesangial cells with antioxidants normalizes
G-induced increases in ECM synthesis (72). Reactive
xygen species also can activate cell signaling pathways such
s PKC, mitogen-activated protein kinases, and JAK-
TAT (73–75). Of particular interest is the activation of
pecific isoforms of PKC (e.g., PKC-beta). The use of PKC
nhibitor compounds such as ruboxistaurin appears to pre-
ent or reverse damage to organs such as the retina (76,77).
he direct effects of these compounds on ECM production
ave not yet been evaluated, but their long-term use does
mprove renal function in diabetic mice (78).
IGNALING
s can be ascertained from the topics discussed previously,
he accumulation of AGEs, the activation of PKC isoforms,
nd HG-induced generation of ROS may explain partly how
yperglycemia mediates tissue damage and remodeling. How
hese events are triggered by HG is less clear. However,
xperimental studies have attempted to identify HG-activated
ell signaling pathways associated with ECM production. In
esangial cell lines transfected with a gene expressing
uciferase and murine collagen IV gene, HG stimulated
uciferase activity in a dose- and time-dependent manner. Ghe inhibition of PKC with staurosporine or calphostin C
ignificantly reduced the activity, suggesting that HG pro-
otes transcriptional activity of collagen IV through PKC
79). Cultured dermal fibroblasts from non–insulin-
ependent DM rats have lower cell proliferation and higher
-lactate accumulation when cultured under normal glucose
onditions versus controls. When incubated in HG, fibro-
lasts from control and DM rats decreased total DNA
ontent and increased L-lactate levels. A PKC inhibitor
eversed HG-induced changes in both cell types, as well as
n the cells from DM rats cultured under NG, suggesting
hat PKC may play a role as a modulator of fibroblast
roliferation in patients with diabetes (80). In a follow-up
tudy by the same group, they also demonstrated the
nvolvement of protein kinase A and cAMP (81).
An excessive accumulation of intracellular sorbitol found
n diabetic animals and in cells cultured under HG condi-
ions has been proposed as important factor in the patho-
enesis of diabetic complications (82). Aldose reductase, a
ey enzyme of polyol pathway, catalyzes NADPH-
ependent reduction of glucose to sorbitol (sorbitol path-
ay). To examine the role of the polyol pathway in renal
CM accumulation, Bleyer et al. (83) incubated murine
roximal tubule cells in either normal or HG concentrations
n the presence or absence of the aldose reductase inhibitor
orbinil. They noted that HG increased cell sorbitol levels
even-fold and the addition of sorbinil inhibited the re-
ponse. In HG cells, sorbinil also reduced mRNA levels of
ollagen type I and IV as well as their secretion.
igure 2. Sorbitol signaling pathway proposed for high-glucose–mediated
nhanced collagen production in fibroblasts. Increases in intracellular
lucose concentrations can activate an enhancer sequence in the collagen
romoter, yielding enhanced collagen production and fibrosis. Increases in
iacylglycerol can occur secondary to the altered transcription of enzymes
nvolved in its synthesis or degradation (e.g., diacylglycerol kinase). The
nhanced entry of glucose into the fibroblasts can also occur independently
f transporter proteins yielding the stimulation of sorbitol and the
roduction of 3-deoxyglucosone and glyoxal (intracellular advanced glyco-
ylation end-product [AGEs]), both of which are direct stimulants of protein
inase C-beta. The production of aldose reductase (AR) also can be favored by
n enhanced transcription of the gene. The sorbitol pathway can also increase
roduction of reactive oxygen species (ROS), further stimulating PKC-beta.
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Diabetes and Cardiac Fibrosis February 21, 2006:693–700The topic of HG-mediated signaling and organ pathol-
gy has been extensively reviewed elsewhere (68,77,84–87).
owever, it is reasonable to assume that in the development
f cardiac fibrosis, HG-activated signaling pathways may
arallel those known to be involved in other diabetic organs.
igure 2 illustrates one such possible scenario that involves
ene transcription, effects of sorbitol, aldose reductase,
OS, and AGEs. A DAG signaling pathway also can be
roposed for HG-mediated enhanced production of ECM
roteins (Fig. 3) (77). As we have demonstrated, Ang II
T1 receptor levels increase in fibroblasts exposed to HG
onditions, and this receptor couples with the production of
AG (56). The enzyme in charge of the interconversion of
his messenger, DAG kinase, allows the synthesis of other
ipid mediators, which can enter the pathway for the
ynthesis of dihydroacetone, increasing ROS and stimulat-
ng PKC-beta and/or protein kinase A. However, dihy-
roacetone also can generate DAG (87). There may also be
rotein kinase-independent effects mediated via AT1 recep-
ors, which may alter the production and/or activity of
CM-related genes. Among all of the well-characterized
KC-independent signaling responses associated with HG,
here is emerging evidence for the involvement of the
ranscription factor nuclear factor kappa B and mitogen-
ctivated protein kinases (88). Alternative pathways for HG-
nduced ECM overproduction have been described and in-
igure 3. Diacylglycerol (DAG) signaling pathway proposed for high-
lucose–mediated enhanced production of extracellular matrix (ECM)
roteins in fibroblasts. High glucose can affect the manner in which
broblasts respond to angiotensin II. Angiotensin II AT1 receptor levels
ncrease in cells treated with high glucose. The stimulation of AT1
eceptors increases the intracellular concentration of DAG. The enzyme in
harge of the interconversion of this messenger DAG kinase (DAGK)
avors the synthesis of other lipid mediators, which can enter the pathway
or the synthesis of dihydroacetone, increase reactive oxygen species, and
timulate protein kinase C (PKC)-beta and/or protein kinase A (PKA).
ihydroacetone can also generate DAG via the action of phosphatidic acid
hosphatase (PAP). There also may be protein kinase-independent effects
ediated via AT1 receptors, which may alter the production and/or activity
f matrix metalloproteinases (MMPs) or other ECM-related genes.
hosphofructokinase (PFK1) is a rate-limiting enzyme involved in the
exosamine pathway. GLUT-1  glucose transporter-1; MAPK 
itogen-activated protein kinase; NF-B nuclear factor kappa B; PLC
phospholipase C beta.lude the hexosamine synthesis pathway (89). The increasedoad of intracellular glucose in handled by a rate limiting
nzyme phosphofructokinase (Fig. 3). When the production of
hosphofructokinase is halted, excess fructose-6-phosphate
llows the synthesis of glucosamine-6-phosphate an activator
f PKC-beta.
ONCLUDING REMARKS
lthough the first reference made to the existence of a
iabetic cardiomyopathy occurred in 1972, limited progress
as been made in attempting to describe the underlying
olecular pathology, and in particular that related to the
evelopment of myocardial fibrosis. Most of the current
nowledge about how hyperglycemia may affect the depo-
ition of ECM proteins comes from studies performed in
idney cells. Although there may be some degree of analogy
etween cellular responses to HG, there can be clear
ifferences depending on the cell type studied. In the
resence of an ever growing incidence of diabetes, it will
ecome imperative to further our understanding of the
nderlying pathology of myocardial fibrosis so as to develop
mproved pharmacological therapies.
eprint requests and correspondence: Dr. Francisco J. Villarreal,
CSD, 9500 Gilman Drive, La Jolla, California 92093-0613J.
-mail: fvillarr@ucsd.edu.
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